High Plasma Osteopontin Level and Its Relationship with Interleukin-12–mediated Type 1 T Helper Cell Response in Tuberculosis

Koguchi, Yoshinobu; Kawakami, Kazuyoshi; Uezu, Kaori; Fukushima, Kiyoyasu; Kon, Sigeyuki; Maeda, Masahiro; Nakamoto, Atsushi; Owan, Isoko; Kuba, Mutsuo; Kudeken, Norifumi; Azuma, Masato; Yara, Satomi; Shinzato, Takashi; Higa, Futoshi; Tateyama, Masao; Kadota, Jun Ichi; Mukae, Hiroshi; Kohno, Shigeru; Uede, Toshimitsu; Saitô, Atsushi

doi:10.1164/rccm.200209-1113oc

Cited by 91 publications

(98 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated values of circulating osteopontin have been described in a wide span of neoplastic localisations from lung to breast, colon and ovarian cancers to some non tumoural pathologies as for example tuberculosis [99]. Assaying this molecule may raise some practical concerns since we have at least three kits available on the market (from Immunobiological Laboratories, Assays Design and R&D Systems) which may not give similar results [100] but data from mesothelioma series shows similar diagnostic capabilities whichever kit is used.…”

Section: Osteopontinmentioning

confidence: 99%

Clinical utility of diagnostic markers for malignant pleural mesothelioma

Grigoriu

Grigoriu²,

Chahine

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Malignant mesothelioma has a very dismal prognosis with very few patients surviving one year after diagnosis. Early multimodal treatment, however, is expected to improve the outcome. Today, there is a strong need to have disease markers which could be used for screening, diagnosing, and/or monitoring tumour response to treatment. Old markers such as hyaluronic acid, various cytokeratin fragments (CYFRA 21.1, TPA) and other cancer antigens (CA 15.3, CA 125 or CA 19.9 or CEA) are not sensitive or specific enough and cannot be used in practice. More recently new molecules, such as soluble mesothelin and osteopontin, have been proposed for diagnostic purposes. Soluble mesothelin has a good specificity but has a suboptimal sensitivity being negative in all sarcomatoid and in up to one half of epithelioid mesothelioma. On the contrary osteopontin has an inadequate specificity. Combining different markers together does not lead to an improvement in diagnostic accuracy. Neither marker can be used for screening purposes, the main limitation being the very low incidence of the disease in the at-risk, asbestos exposed population. Mesothelin is also a promising marker for monitoring response to treatment but published data is still insufficient to make recommendations. There is still a strong need for research is this area both in order to discover new markers as well as to correct the positioning of each existing molecule (alone or in combination) is the evaluation of the patients with a mesothelioma.

show abstract

Section: Osteopontinmentioning

confidence: 99%

Clinical utility of diagnostic markers for malignant pleural mesothelioma

Grigoriu

Grigoriu²,

Chahine

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

show abstract

“…Authors' Affiliations: 1 in various nonpleural malignant diseases (8 -10) and elevated serum osteopontin levels have been reported in ovarian, colon, breast, prostate, and lung cancers (11,12) or in tuberculosis (13). Osteopontin is an extracellular cell adhesion protein involved in nonmineral bone matrix formation, but is also a key cytokine in mediating type I immune responses (14), and was implicated in regulation of metastatic spread of tumor cells (15).…”

Section: Imaging Diagnosis Prognosismentioning

confidence: 99%

Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment

Grigoriu

Scherpereel

Devos

et al. 2007

Clinical Cancer Research

203

197

View full text Add to dashboard Cite

Purpose: Malignant mesothelioma is a highly aggressive tumor and is often diagnosed too late for a curative treatment.We compared diagnostic and prognostic values of mesothelin and osteopontin in172 patients suspected of malignant pleural mesothelioma (MPM) and in a control group of 112 asymptomatic asbestos-exposed subjects. Experimental Design: Osteopontin and mesothelin were assayed with commercial ELISA kits in a series of 43 patients with pleural metastases of various carcinomas, 33 patients with benign pleural lesions associated with asbestos exposure, 96 patients with MPMs, and 112 asbestosexposed healthy subjects. Results were correlated with patient's diagnosis and survival. Results: Serum osteopontin level was higher in MPM patients compared with healthy asbestosexposed subjects and had a good capability to distinguish between these two populations. However, osteopontin was unable to distinguish between MPM and pleural metastatic carcinoma or benign pleural lesions associated with asbestos exposure. Neither plasma nor pleural fluid osteopontin were more powerful in this respect. Serum mesothelin had a good ability for diagnosing MPM but was unable to identify patients with nonepithelioid mesothelioma subtypes. Survival analysis identified tumor histologic subtype along with serum osteopontin and serum mesothelin as independent prognostic factors in mesothelioma patients. Conclusions: Osteopontin has a lower diagnostic accuracy than mesothelin in patients suspected of MPM. Insufficient specificity limits osteopontin utility as diagnostic marker. Both molecules have a potential value as prognostic markers.

show abstract

“…We assume that the quinolone treatment may be one of the factors of persistent OPN elevation. The increased plasma OPN in TB patients contributed to the disease pathology by activating the IL-12 mediated Th1 immunity (Koguchi et al 2003). It was also found that OPN expression correlates with an effective inflammatory response and contributes to human resistance against MTB (Nau et al 2000).…”

Section: Discussionmentioning

confidence: 94%

Distinct Clinical Features in Nontuberculous Mycobacterial Disease with or without Latent Tuberculosis Infection

Siddiqi

Chagan-Yasutan

Nakajima

et al. 2012

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Nontuberculous mycobacteria (NTM) diseases are in the face of a progressive increase even in immune-competent subjects, and the clinical features of NTM diseases are heterogenous. The decision to institute treatment of the patients should be made after a period of follow up, because therapy is often prolonged, and frequently ineffective. The reasons why some patients develop severe NTM diseases are not clear. Here we observed the involvement of latent tuberculosis infection (LTBI) in clinical and laboratory features of NTM diseases. We evaluated various tuberculosis-related inflammatory markers including osteopontin (OPN), pentraxin-3 (PTX-3), and soluble IL-2 receptor (sIL-2R) in NTM infected patients with or without LTBI. Eight NTM and 5 tuberculosis (TB) patients, and 5 healthy subjects were enrolled. Polymerase Chain Reaction (PCR) analysis confirmed the absence of tuberculosis specific gene (RD1 region), among clinical isolates from NTM patients. Interferon-γ (IFN-γ) release assay (IGRA) using Early Secreted Antigenic Target-6 (ESAT-6) and CFP-10, the RD1-encoded protein, was employed for determining LTBI. IGRA was positive in 4/8 NTM (NTM with LTBI, 50%) and 5/5 TB patients. Only 2 of 4 NTM with LTBI were under chemotherapy among all NTM patients, and others were followed up. The plasma levels of OPN, PTX3 and sIL-2R were significantly higher in NTM patients with LTBI than in those without LTBI (P < 0.05). The two patients under therapy showed the highest OPN levels that persisted after treatment. The increased inflammatory levels in NTM patients with LTBI indicate enhanced inflammatory reaction. Extensive therapy may be necessary in such patients.

show abstract

High Plasma Osteopontin Level and Its Relationship with Interleukin-12–mediated Type 1 T Helper Cell Response in Tuberculosis

Cited by 91 publications

References 36 publications

Clinical utility of diagnostic markers for malignant pleural mesothelioma

Clinical utility of diagnostic markers for malignant pleural mesothelioma

Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment

Distinct Clinical Features in Nontuberculous Mycobacterial Disease with or without Latent Tuberculosis Infection

Contact Info

Product

Resources

About